(Bloomberg) — A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen.The vaccine increased levels of both protective neutralizing antibodies and immune T-cells that target the virus, according to the study organizers. The results were published Monday in The Lancet medical journal.AstraZeneca shares rose as much as 10% in London but gave up much of gain to trade 0.6% higher as researchers cautioned that the results were preliminary. A positive outcome had been widely expected after …read more
Source:: Yahoo Finance
